西地那非更高剂量治疗新生儿脑病继发脑损伤的1b期剂量探索试验
这项1b期开放标签剂量探索试验在治疗性低温下给中重度缺氧缺血性脑病(HIE)且日龄2天MRI确认脑损伤的新生儿使用肠内西地那非,从2.0 mg/kg起始,第3剂起分2.5 mg/kg q12h与3.0 mg/kg q12h两组,主要结局为剂量限制性毒性。13例接受西地那非,3.0 mg/kg q12h安全且耐受良好,需2期试验评估多中心可行性与疗效。
要点
- 中重度HIE低温治疗下肠内西地那非最高3.0 mg/kg q12h安全且耐受良好。
- 组1首剂后25%(2/8)出现短暂低血压,与抗癫痫药相关;组2分开给药未见显著低血压。
- 18月龄死亡或显著神经发育损害组1为50%(4/8)、组2为60%(3/5)。
核心结论
- 在小型单中心HIE低温治疗队列中,肠内西地那非最高3.0 mg/kg q12h安全且耐受良好。
- 需开展2期试验评估多中心可行性与疗效。
研究设计与样本
- 1b期开放标签剂量探索临床试验,纳入低温治疗下中重度HIE且日龄2天MRI确认脑损伤的新生儿。
- 肠内西地那非每12小时给药共7天,初始剂量2.0 mg/kg、第二剂2.5 mg/kg,第3剂起组1为2.5 mg/kg q12h、组2为3.0 mg/kg q12h。
- 主要结局为剂量限制性毒性发生率,次要结局探索日龄30天神经影像与18月龄神经发育。
主要发现
- 组1中25%(2/8)首剂后出现短暂低血压,与抗癫痫药相关。
- 组2分开给药时未发生显著低血压。
- 3.0 mg/kg/剂时稳态西地那非浓度持续超过低温治疗期。
- 18月龄死亡或显著神经发育损害组1为50%(4/8)、组2为60%(3/5)。
- 存活者中脑损伤部分恢复组1为80%(4/5)、组2为75%(3/4);脑瘫组1为0%(0/5)、组2为50%(2/4)。
关键数值与推荐
- 纳入标准:中重度HIE且日龄2天MRI确认脑损伤,并接受治疗性低温。
- 给药方案:肠内西地那非q12h共7天,初始2.0 mg/kg、第二剂2.5 mg/kg,第3剂起组1 2.5 mg/kg q12h、组2 3.0 mg/kg q12h。
- 主要结局为剂量限制性毒性发生率。
临床怎么用
- 对低温治疗下中重度HIE伴脑损伤新生儿,肠内西地那非最高3.0 mg/kg q12h在该小队列中安全且耐受良好。
- 首剂后短暂低血压与抗癫痫药相关,分开给药时组2未发生显著低血压,提示给药安排需考虑合并用药。
- 目前证据仅来自小型单中心1b期试验,疗效需2期试验验证,尚不能用于常规临床决策。
局限性
- 小型单中心开放标签剂量探索试验,样本量小(13例接受西地那非)。
- 缺乏对照组,安全性及神经发育结局需2期试验进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the safety and tolerability of higher doses of sildenafil in neonates with hypoxic-ischemic encephalopathy (HIE) and brain injury. STUDY DESIGN: A phase 1b open-label dose-finding clinical trial in neonates with moderate-severe HIE and confirmed brain injury on a day-2 magnetic resonance imaging during therapeutic hypothermia (TH). Enteral sildenafil was administered every 12 hours (q12 h) for 7 days. All participants received an initial dose 2.0 mg/kg, and a second dose of 2.5 mg/kg. Starting from the third dose, group 1 received 2.5 mg/kg q12 h and group 2 received 3.0 mg/kg q12 h. Primary outcome was incidence of dose-limiting toxicities. Secondary outcomes explored day-30 neuroimaging and 18-month neurodevelopment. RESULTS: Among the 30 neonates born between October 2019 and December 2021, 20 displayed day-2 brain injury and 13 received sildenafil (8 in group 1; 5 in group 2). In group 1, 25% (2/8) experienced transient hypotension after the first dose, linked to antiseizure medications. No significant hypotension occurred in group 2 when sildenafil was administered separately. At the 3.0 mg/kg/dose, steady-state sildenafil concentrations persisted beyond TH. Death or significant 18-month neurodevelopmental impairment occurred in 50% (4/8) of group 1 and 60% (3/5) of group 2. Among the survivors, partial recovery of brain injury was seen in 80% (4/5) of group 1 and 75% (3/4) of group 2; cerebral palsy developed in 0% (0/5) and 50% (2/4), respectively. CONCLUSIONS: Enteral sildenafil up to 3.0 mg/kg q12 h was safe and well tolerated in a small single-center cohort of neonates with HIE treated with TH. Phase 2 trials are needed to assess multicenter feasibility and efficacy. TRIAL REGISTRATION: ClinicalTrials.gov NCT04169191.
引用
- Wintermark P, Lapointe A, Altit G, et al. Testing Higher Doses of Sildenafil to Repair Brain Injury Secondary to Birth Asphyxia: An Open-Label Dose-Finding Phase 1b Clinical Trial-Sildenafil Administration to Treat Neonatal Encephalopathy-Study 02. J Pediatr. 2025. PMID: 40562301. doi:10.1016/j.jpeds.2025.114701
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。